Lisa Hwa, APRN, DNP, CNP, FAPO

Following the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.

Experts on multiple myeloma address the intricacies of adverse event management practices, focusing on taste changes and associated weight loss.

Samantha Shenoy, NP, MSN, presents the case of a patient with multiple myeloma and the panel discusses adverse event management practices.

The panel provides an overview of REMS programs for bispecific therapies in multiple myeloma and discusses how institutions can educate healthcare professionals outside of oncology.

Experts on multiple myeloma discuss prophylactic supportive measures to prevent CRS and ICANS in patients who receive GPRC5D therapy.

Mary Steinbach, APRN, shares her experience in managing dysgeusia and nail- and skin-related toxicities seen in patients with multiple myeloma who receive talquetamab.

Focusing on patients with multiple myeloma who receive GPRC5D-targeted therapy, Beth Faiman, CNP, PhD, discusses how long-term treatment impacts patients’ tolerance to adverse events.

Experts on multiple myeloma offer clinical insights on preparing patients who are going to receive GPRC5D therapy, highlighting step-up and treatment dosing for talquetamab.

Beth Faiman, CNP, PhD, outlines unique toxicities seen with other GPRC5D-targeted therapies in multiple myeloma.

Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.

Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.

Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.

A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.